کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
4061334 | 1604017 | 2013 | 5 صفحه PDF | دانلود رایگان |

This randomized trial evaluated the effect of zoledronic acid on femoral bone mineral density (BMD) following primary total hip arthroplasty. Bone mineral density was compared for up to 2 years in 27 patients receiving 5 mg zoledronic acid intravenous infusion and in 24 patients receiving placebo at 2 weeks and 1 year after surgery. Zoledronic acid prevented loss of bone mineral density at 1 year (+ 13.8% vs + 1.4%, P = .0065) and 2 years (+ 14.3% vs − 4.0%, P < .0001) in Gruen zone 1, at 1 year (− 8.4% vs − 25.4%, P < .0001) and 2 years (− 9.6% vs − 27.3%, P < .0001) in Gruen zone 7, at 6 weeks, 6 months, and 1 or 2 years in Gruen zones 4 and 6. For all Gruen zones, prevention of BMD loss by ZOL was significant at 6 weeks, 6 months, 1 year (+ 0.80% vs − 6.03%, P < .0001) and 2 years (-0.16% vs − 7.13%, P < .0001).
Journal: The Journal of Arthroplasty - Volume 28, Issue 4, April 2013, Pages 671–675